Rosenthal AK, Ryan LM. Calcium Pyrophosphate Deposition Disease.
N Engl J Med 2016;374:2575–84.
1 Rosenthal AK, Ryan LM. Calcium Pyrophosphate Deposition Disease. N Engl J Med. 2016;374:2575–84.
2 Richette P, Bardin T. Calcium pyrophosphate deposition disease. Presse Med. 2011;40:856–64.
3 Zhang W, Doherty M, Bardin T, Barskova V, Guerne PA, et al. European League Against Rheumatism recommendations for calcium pyrophosphate deposition. Part I: terminology and diagnosis. Ann Rheum Dis. 2011;70:563–70.
4 Richette P, Bardin T, Doherty M. An update on the epidemiology of calcium pyrophos-phate dihydrate crystal deposition disease. Rheumatology (Oxford). 2009;48:711–5.
5 Miksanek J, Rosenthal AK. Imaging of calcium pyrophosphate deposition disease. Curr Rheumatol Rep. 2015;17:20.
6 Filippou G, Adinolfi A, Iagnocco A, Filippucci E, Cimmino MA, et al. Ultrasound in the di-agnosis of calcium pyrophosphate dihydrate deposition disease. A systematic literature review and a meta-analysis. Osteoarthritis Cartilage. 2016;24:973–81.
7 Ellabban A, Kamel SR, Omar HA, El-Sherif AM, Abdel-Magied RA. Ultrasonographic di-agnosis of articular chondrocalcinosis. Rheumatol Int. 2012;32:3863–8.
8 Ottaviani S, Juge PA, Aubrun A, Palazzo E, Dieudé P. Sensitivity and Reproducibility of Ultrasonography in Calcium Pyrophosphate Crystal Deposition in Knee Cartilage: A Cross-sectional Study. J Rheumatol. 2015;42:1511–3.
9 Sivera F, Andrés M, Pascual E. Current advances in therapies for calcium pyrophosphate crystal arthritis. Curr Opin Rheumatol. 2016;28:140–4.
10 Zhang W, Doherty M, Pascual E, Barskova V, Guerne PA et al. EULAR recommenda-tions for calcium pyrophosphate deposition. Part II: management. Ann Rheum Dis. 2011;70:571–5.
11 Alvarellos A, Spilberg I. Colchicine prophylaxis in pseudogout. J Rheumatol. 1986;13:804–5.
12 Doherty M, Dieppe PA. Double blind, placebo controlled trial of magnesium carbonate in chronic pyrophosphate arthropathy. Ann Rheum Dis. 1983;42(Suppl):106.
13 Chollet-Janin A, Finckh A, Dudler J, Guerne PA. Methotrexate as an alternative therapy for chronic calcium pyrophosphate deposition disease: an exploratory analysis. Arthritis Rheum. 2007;56:688–92.
14 Andres M, Sivera F, Pascual E. Methotrexate is an option for patients with refractory cal-cium pyrophosphate crystal arthritis. J Clin Rheumatol. 2012;18:234–6.
15 Finckh A, Mc Carthy GM, Madigan A, Van Linthoudt D, Weber M. Methotrexate in chron-ic-recurrent calcium pyrophosphate deposition disease: no significant effect in a random-ized crossover trial. Arthritis Res Ther. 2014;16:458.
16 Pascual E, Andrés M, Sivera F. Methotrexate: should it still be considered for chronic calcium pyrophosphate crystal disease? Arthritis Res Ther. 2015;17:89.
17 Luzar MJ, Altawil B. Pseudogout following intraarticular injection of sodium hyaluronate. Arthritis Rheum. 1998;41:939–40.